WO2012088247A3 - Fragments et anticorps anti-c5/c5a/c5adesr - Google Patents

Fragments et anticorps anti-c5/c5a/c5adesr Download PDF

Info

Publication number
WO2012088247A3
WO2012088247A3 PCT/US2011/066437 US2011066437W WO2012088247A3 WO 2012088247 A3 WO2012088247 A3 WO 2012088247A3 US 2011066437 W US2011066437 W US 2011066437W WO 2012088247 A3 WO2012088247 A3 WO 2012088247A3
Authority
WO
WIPO (PCT)
Prior art keywords
c5adesr
polypeptide
antibodies
antigen
fragments
Prior art date
Application number
PCT/US2011/066437
Other languages
English (en)
Other versions
WO2012088247A2 (fr
Inventor
Caroline COLLEY
Claire Dobson
Joanne BRENNAN
Sek Fung
Original Assignee
Medimmune, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune, Llc filed Critical Medimmune, Llc
Priority to CA2822288A priority Critical patent/CA2822288A1/fr
Publication of WO2012088247A2 publication Critical patent/WO2012088247A2/fr
Publication of WO2012088247A3 publication Critical patent/WO2012088247A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La présente invention concerne des compositions, des procédés de fabrication et des procédés d'utilisation se rapportant à des anticorps anti-C5/C5a/C5adesR et à des fragments de liaison à l'antigène.
PCT/US2011/066437 2010-12-22 2011-12-21 Fragments et anticorps anti-c5/c5a/c5adesr WO2012088247A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2822288A CA2822288A1 (fr) 2010-12-22 2011-12-21 Fragments et anticorps anti-c5/c5a/c5adesr

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061426021P 2010-12-22 2010-12-22
US61/426,021 2010-12-22

Publications (2)

Publication Number Publication Date
WO2012088247A2 WO2012088247A2 (fr) 2012-06-28
WO2012088247A3 true WO2012088247A3 (fr) 2012-09-20

Family

ID=46314882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/066437 WO2012088247A2 (fr) 2010-12-22 2011-12-21 Fragments et anticorps anti-c5/c5a/c5adesr

Country Status (2)

Country Link
CA (1) CA2822288A1 (fr)
WO (1) WO2012088247A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
EP3689912A1 (fr) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
EP4238993A3 (fr) 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène capable de se lier à deux ou plusieurs molécules d'antigène de manière répétée
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
DK3798230T3 (en) * 2011-06-06 2022-10-31 Novo Nordisk As Terapeutiske antistoffer
US20160271216A1 (en) * 2013-08-09 2016-09-22 Apellis Pharmaceuticals, Inc. Compositions and methods relating to c5l2
BR112016015589A2 (pt) * 2014-01-06 2017-10-31 Hoffmann La Roche módulos de trânsito monovalentes para a barreira hematoencefálica
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
SG11201607165YA (en) 2014-12-19 2016-09-29 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
EP3494991A4 (fr) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Composition pour la prophylaxie ou le traitement de maladies liées à il-8
EP3529619B1 (fr) * 2016-10-19 2021-06-30 Alexion Pharmaceuticals, Inc. Procédé de quantification de c5a non lié dans un échantillon
EP3529618B1 (fr) * 2016-10-19 2020-12-02 Alexion Pharmaceuticals, Inc. Procédé de quantification de c5 non liée dans un échantillon
CA3057146A1 (fr) * 2017-03-23 2018-09-27 The Trustees Of The University Of Pennsylvania Anticorps anti-c5a et utilisations de ceux-ci
US11472889B2 (en) 2017-10-14 2022-10-18 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
EP3853249A4 (fr) * 2018-09-21 2022-06-22 The University of North Carolina at Chapel Hill Agents de liaison synthétiques permettant de limiter la perméation à travers le mucus
EP4172200A1 (fr) * 2020-06-24 2023-05-03 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Anticorps reconnaissant de manière spécifique c5a et leurs utilisations
CN114149501B (zh) * 2020-12-11 2023-05-26 天士力生物医药股份有限公司 抗c5抗体及其应用
CN116670288A (zh) * 2021-12-22 2023-08-29 舒泰神（北京）生物制药股份有限公司 一种分离的抗C5a抗体及其制剂与应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058956A2 (fr) * 2000-02-10 2001-08-16 Abbott Laboratories Anticorps de liaison de l'interleukine 18 humaine et procedes de preparation et d'utilisation
US20030099647A1 (en) * 2001-10-05 2003-05-29 Deshpande Rajendra V. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20060286112A1 (en) * 2005-05-16 2006-12-21 Sirid-Aimee Kellermann Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
US20090169562A1 (en) * 2006-06-06 2009-07-02 Mark Throsby Human Binding Molecules Having Killing Activity Against Enterococci and Uses Thereof
US20090286283A1 (en) * 2008-05-16 2009-11-19 Samsung Electronics Co., Ltd. Method and affinity column for purifying proteins
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US20100034809A1 (en) * 2008-08-05 2010-02-11 Novartis Ag Compositions and Methods for Antibodies Targeting Complement Protein C5

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058956A2 (fr) * 2000-02-10 2001-08-16 Abbott Laboratories Anticorps de liaison de l'interleukine 18 humaine et procedes de preparation et d'utilisation
US20030099647A1 (en) * 2001-10-05 2003-05-29 Deshpande Rajendra V. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20060286112A1 (en) * 2005-05-16 2006-12-21 Sirid-Aimee Kellermann Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
US20090169562A1 (en) * 2006-06-06 2009-07-02 Mark Throsby Human Binding Molecules Having Killing Activity Against Enterococci and Uses Thereof
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US20090286283A1 (en) * 2008-05-16 2009-11-19 Samsung Electronics Co., Ltd. Method and affinity column for purifying proteins
US20100034809A1 (en) * 2008-08-05 2010-02-11 Novartis Ag Compositions and Methods for Antibodies Targeting Complement Protein C5

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE UNIPROTKB [online] 4 November 2008 (2008-11-04), retrieved from http://www.uniprot.org/uniprot/B5RTL3 Database accession no. B5RTL3 *
LARRICK ET AL.: "Characterization of Murine Monoclonal Antibodies That Recognize Neutralizing Epitopes on Human C5a.", INFECT LMMUN., vol. 55, no. 8, 1987, pages 1867 - 1872, XP002570405 *
MAHAFFEY ET AL.: "Effect of Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Fibrinolysis in Acute Myocardial Infarction The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) Trial.", CIRCULATION., vol. 108, no. 10, 2003, pages 1176 - 1183 *
RAINARD ET AL.: "Quantification of C5a/C5a(desArg) in bovine plasma, serum and milk.", VET RES., vol. 29, no. 1, 1998, pages 73 - 88 *

Also Published As

Publication number Publication date
WO2012088247A2 (fr) 2012-06-28
CA2822288A1 (fr) 2012-06-28

Similar Documents

Publication Publication Date Title
WO2012088247A3 (fr) Fragments et anticorps anti-c5/c5a/c5adesr
WO2010136311A3 (fr) Compositions et procédés de ciblage de la protéine c3b de complément par des anticorps
WO2013173761A3 (fr) Protéines de liaison à l'antigène st2
WO2013011076A3 (fr) Protéines de liaison à un antigène ayant une liaison accrue à fcrn
IN2014MN00873A (fr)
WO2010017103A3 (fr) Anticorps monoclonaux anti-nkg2d humain entièrement humains
WO2013043933A3 (fr) Protéines de liaison à un antigène cd27l
WO2011146514A3 (fr) Isolement rapide d'anticorps monoclonaux à partir d'animaux
MX353931B (es) Anticuerpos que se unen a ox40 y sus usos.
WO2009081285A3 (fr) Anticorps contre le virus de l'hépatite c
WO2011032161A8 (fr) Vaccins dirigés contre les cellules de langerhans
IN2012DN02634A (fr)
PH12013502205A1 (en) Antibodies to il-6 and their uses
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
WO2011004028A3 (fr) Agents de liaison à tlr3
WO2012156532A8 (fr) Anticorps anti-her3 humain et leurs utilisations
MA34004B1 (fr) Protéines de liaison à cd127
WO2011002968A3 (fr) Polypeptides et procédé de traitement
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2011092593A3 (fr) Anticorps neutralisant le vih-1 et leurs utilisations
MX2010001237A (es) Nuevos anticuerpos.
WO2012125733A3 (fr) Méthodes de dépistage d'anticorps
WO2008098917A3 (fr) Nouveaux anticorps
PH12020550825A1 (en) Anti-c5 antibody combinations and uses thereof
WO2010118203A3 (fr) Molécules de liaison à l'endosialine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11850408

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2822288

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013546366

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 11850408

Country of ref document: EP

Kind code of ref document: A2